All publications

Export 169 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
L
Leigh Brown A, Lycett S, Weinert L, Hughes GJ, Fearnhill E, Dunn DT, UK Collaborative Group on HIV Drug Resistance.  2011.  HIV transmission dynamics. Keystone Conference on HIV Evolution, Genomics and Pathogenesis, 26-31March 2011.
Leigh Brown A, Lycett S, Weinert L, Hughes GJ, Fearnhill E, Dunn DT, UK HIV Drug Resistance Database.  2010.  Analysis of the Degree Distribution of HIV Transmission Networks Inferred from Viral Sequence Data. 17th Conference on Retroviruses and Opportunistic Infections, February 2010.
Leigh Brown A, Lycett S, Weinert L, Hughes GJ, Fearnhill E, Dunn DT.  2011.  Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 204:1463-9.
Lewis F, Fearnhill E, Murray R, Pillay D, Dunn DT, Leigh Brown A, UK Collaborative Group on HIV Drug Resistance.  2006.  Bayesian models in the analysis of HIV drug resistance data from the UK HIV Drug Resistance Database. 15th International HIV Drug Resistance Workshop, 13-17 June 2006.
Lodi S, Günthard HF, Dunn DT, Garcia F, Logan R, Jose S., Bucher HC, Scherrer AU, Schneider M-P, Egger M et al..  2018.  Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance.. AIDS. 32(3):327-335.
M
Mackie N, Garvey L, Geretti AM, Harrison LJ, Tilston P, Phillips AN, Sabin CA, Dunn DT.  2011.  Predicting NNRTI resistance - do polymorphisms matter? 18th Conference on Retroviruses and Opportunistic Infections, 27 Feb - 2 Mar 2011.
Mackie N, Phillips AN, Kaye S, Booth C, Geretti AM.  2010.  Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.
Mackie N, Dunn DT, Dolling D, Garvey L, Harrison LJ, Fearnhill E, Tilston P, Sabin CA, Geretti AM.  2013.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.
Mbisa JL, Kirwan P, Bibby D., Brown A, Myers R.E, Murphy G., Ledesma J, Asboe D, Pozniak A, Sabin CA et al..  2017.  Source of HIV-1 drug-resistant minority variants in people who are recently infected. 24th International HIV Dynamics and Evolution.
Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS, Murphy G, Asboe D et al..  2018.  Determining the origins of HIV-1 drug-resistant minority variants in people who are recently infected using phylogenetic reconstruction.. Clin Infect Dis.
Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Asboe D, Cane P A.  2015.  Evidence of Self-Sustaining Drug Resistant HIV-1 Lineages Among Untreated Patients in the United Kingdom. Clin Infect Dis. 61:829-36.
Mbisa JL, Fearnhill E, Dunn DT, Pillay D, Cane P A, UK HIV Drug Resistance Database.  2014.  Sustained Spread of HIV-1 Drug Resistance in Treatment-Naïve Patients in the United Kingdom. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.
Mbisa JL, Kirwan P, Bibby D., Brown A, Myers R.E, Murphy G., Ledesma J, Asboe D, Pozniak A, Sabin CA et al..  2017.  Source of HIV-1 drug-resistant minority variants in people who are recently infected. BHIVA Spring.
Mourad R, Chevennet F, Dunn DT, Fearnhill E, Asboe D, Gascuel O, Hue S.  2014.  Transmission and persistence of antiretroviral resistance amongst drug naïve HIV positive individuals in the United Kingdom. International Workshop on Antiviral Drug Resistance, June 2014.
Mourad R, Chevennet F, Dunn DT, Fearnhill E, Delpech V, Asboe D, Gascuel O, Hue S.  2015.  A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK. AIDS. 29:1917-25.
Mulka L, Ragonnet-Cronin M, Tostevin A, Dunn DT, Leigh Brown A.  2017.  Identifying the sources of recent HIV infection in a UK cohort. 24th International HIV Dynamics and Evolution.
P
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2005.  Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS. 19:487-94.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2004.  Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice. 13th International Drug Resistance Workshop, 8-12 June 2004.
Phillips AN, Dunn DT, Sabin CA, Pozniak A, Matthias R, Geretti AM, Clark J, Churchill D, Williams I, Hill T et al..  2004.  Long term risk of development of drug resistance after starting antiretroviral therapy in routine clinical practice. 7th International Congress on Drug Therapy in HIV Infection, 14-17 November 2004.